Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI?
XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite?
Overview
While State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to established healthcare giants at a minimal cost, State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides a more volatile, equal-weighted focus on the biotechnology sub-sector.
Choosing between these two funds depends on the desired level of industry concentration and volatility tolerance. The State Street Health Care Select Sector SPDR ETF provides a diversified entry into the healthcare giants of the S&P 500, whereas the smaller State Street SPDR S&P Biotech ETF leans heavily into the high-risk potential of research-focused firms. This comparison analyzes cost, performance, and risk profiles to see which approach fits your portfolio.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Source
Originally published at www.fool.com.
Related Articles
- Here are Monday's biggest analyst calls: SpaceX, Nvidia, Tesla, Applied Materials, Circle, Corning, GE Vernova & more
- Greece wildfire in pictures: Firefighters battle blaze worsened by 100km per hour winds
- Amazon.com vs. CAVA: Which Consumer Stock Is a Better Buy in 2026, the Veteran E-Commerce Giant or Rising Restaurant Chain?